Corona Remedies Limited ranks among the top 30 pharmaceutical companies in the Indian Pharmaceutical Market (IPM

CORONA Corona Remedies Limited ranks among the top 30 pharmaceutical companies in the Indian Pharmaceutical Market (IPM). It focuses heavily on chronic care and therapeutic segments, capturing strong market positions:Women's Healthcare: Ranked #5 in India, reaching roughly 85% of gynecologists and IVF specialists ***** Management: Ranked #5 in India, offering formulations for acute and chronic pain ***** Ranked #20, addressing metabolic and cardiovascular ***** Ranked #9, focusing on specialist-driven urological medications.📊 Stock & Financial HighlightsCorona Remedies is a publicly traded entity on the Indian stock ***** Capitalization: Approximately ₹13,063 ***** Price: Trading at around ₹2,***** Metrics: It has delivered a strong profit growth of 23.3% CAGR over the past 5 years with a 3-year Return on Equity (ROE) of 26.5%.Dividend Yield: The company maintains a healthy dividend payout ratio of 29.4%.💡 Recent DevelopmentsThe company recently commercialised its state-of-the-art, EU-approved Women's Hormone Manufacturing Facility in Bhayla, Ahmedabad. This 1.0 lakh sq. ft. facility expands their capacity to 194 million tablets/capsules annually, driving high-margin growth in the specialized hormone therapy market.